Commerzbank Aktiengesellschaft FI lifted its stake in shares of Eli Lilly And Co (NYSE:LLY) by 0.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 82,517 shares of the company’s stock after acquiring an additional 275 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Eli Lilly And Co were worth $9,228,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in LLY. Enterprise Trust & Investment Co bought a new stake in shares of Eli Lilly And Co during the 3rd quarter worth $27,000. Prestige Wealth Management Group LLC bought a new stake in shares of Eli Lilly And Co during the 2nd quarter worth $34,000. Manchester Financial Inc. bought a new stake in shares of Eli Lilly And Co during the 2nd quarter worth $40,000. Litman Gregory Asset Management LLC bought a new stake in shares of Eli Lilly And Co during the 2nd quarter worth $47,000. Finally, Personal Wealth Partners bought a new stake in shares of Eli Lilly And Co during the 2nd quarter worth $53,000. 76.79% of the stock is owned by institutional investors and hedge funds.
Shares of Eli Lilly And Co stock opened at $108.64 on Friday. The stock has a market cap of $104.71 billion, a PE ratio of 19.54, a price-to-earnings-growth ratio of 1.85 and a beta of 0.16. The business has a fifty day simple moving average of $111.18 and a 200-day simple moving average of $114.02. The company has a quick ratio of 0.87, a current ratio of 1.13 and a debt-to-equity ratio of 4.98. Eli Lilly And Co has a 12 month low of $104.17 and a 12 month high of $132.13.
In related news, SVP Alfonso G. Zulueta sold 4,500 shares of the stock in a transaction on Friday, September 20th. The stock was sold at an average price of $117.00, for a total transaction of $526,500.00. Following the completion of the sale, the senior vice president now directly owns 33,806 shares in the company, valued at $3,955,302. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Alfonso G. Zulueta sold 19,500 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $112.91, for a total value of $2,201,745.00. Following the sale, the senior vice president now owns 38,306 shares of the company’s stock, valued at $4,325,130.46. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 243,452 shares of company stock valued at $28,252,925. 0.11% of the stock is owned by corporate insiders.
LLY has been the subject of several recent analyst reports. UBS Group decreased their target price on Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating for the company in a research report on Thursday. ValuEngine cut Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Friday, June 28th. Finally, Bank of America initiated coverage on Eli Lilly And Co in a research report on Wednesday. They issued a “buy” rating and a $133.00 target price for the company. Eight research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Eli Lilly And Co has an average rating of “Buy” and a consensus target price of $127.69.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Further Reading: How does a security become overbought?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.